These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24884319)

  • 21. [Efficacy and safety of bendamustine combined with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma].
    Wang J; Yao Y; Shang JJ; Ma X; Fu CC; Wu DP; Jin S
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):504-507. PubMed ID: 37550209
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients.
    Ghesquières H; Stamatoullas A; Casasnovas O; Morschhauser F; Gyan E; Gabarre J; Malphettes M; Clément L; Ferlay C; Brice P
    Leuk Lymphoma; 2013 Nov; 54(11):2399-404. PubMed ID: 23410099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.
    Farag S; Jeker B; Bacher U; Mansouri Taleghani B; Mueller BU; Novak U; Pabst T
    Hematol Oncol; 2018 Oct; 36(4):671-678. PubMed ID: 30110717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bendamustine: role and evidence in lymphoma therapy, an overview.
    Derenzini E; Zinzani PL; Cheson BD
    Leuk Lymphoma; 2014 Jul; 55(7):1471-8. PubMed ID: 24180334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.
    Cheson BD; Brugger W; Damaj G; Dreyling M; Kahl B; Kimby E; Ogura M; Weidmann E; Wendtner CM; Zinzani PL
    Leuk Lymphoma; 2016; 57(4):766-82. PubMed ID: 26592922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extramedullary relapse of multiple myeloma presenting as space-occupying lesion in liver treated with daratumumab, pomalidomide, dexamethasone and bendamustine.
    Wadhera S; Jain A; Mitra S; Malhotra P
    BMJ Case Rep; 2024 Apr; 17(4):. PubMed ID: 38627054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bendamustine: inadequate or outdated data.
    Prescrire Int; 2012 Mar; 21(125):64. PubMed ID: 22428184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes.
    van der Jagt R
    Expert Rev Hematol; 2013 Oct; 6(5):525-37. PubMed ID: 24125522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bendamustine's emerging role in the management of lymphoid malignancies.
    Rummel MJ; Gregory SA
    Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies.
    Gandhi V
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):4-11. PubMed ID: 12170425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
    Howell M; Gibb A; Radford J; Linton K
    Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
    [No Abstract]   [Full Text] [Related]  

  • 32. Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
    Kumar SK; Krishnan A; LaPlant B; Laumann K; Roy V; Zimmerman T; Gertz MA; Buadi FK; Stockerl Goldstein K; Birgin A; Fiala M; Duarte L; Maharaj M; Levy J; Vij R
    Am J Hematol; 2015 Dec; 90(12):1106-10. PubMed ID: 26331432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bendamustine for relapsed blastic plasmacytoid dendritic cell leukaemia.
    Bétrian S; Guenounou S; Luquet I; Demur C; Huynh A; Ysebaert L; Recher C; Huguet F
    Hematol Oncol; 2017 Jun; 35(2):252-255. PubMed ID: 28620927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients.
    Prediletto I; Farag SA; Bacher U; Jeker B; Mansouri Taleghani B; Brégy R; Zander T; Betticher D; Egger T; Novak U; Pabst T
    Bone Marrow Transplant; 2019 Dec; 54(12):1923-1925. PubMed ID: 30890768
    [No Abstract]   [Full Text] [Related]  

  • 35. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
    Gordon MJ; Lewis LD; Brown JR; Danilov AV
    Expert Rev Hematol; 2017 Aug; 10(8):707-718. PubMed ID: 28664772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bendamustine in patients with relapsed or refractory multiple myeloma.
    Michael M; Bruns I; Bölke E; Zohren F; Czibere A; Safaian NN; Neumann F; Haas R; Kobbe G; Fenk R
    Eur J Med Res; 2010 Jan; 15(1):13-9. PubMed ID: 20159666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bendamustine conditioning for refractory type I cryoglobulinemia.
    Martin M; Lipsker D; Fornecker LM; Toussaint E; Martin T
    Joint Bone Spine; 2016 Oct; 83(5):591-2. PubMed ID: 26677988
    [No Abstract]   [Full Text] [Related]  

  • 38. Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
    Pozzi S; Gentile M; Sacchi S; Marcheselli R; Corso A; Cocito F; Musto P; Guarini A; Minoia C; Vincelli I; Ria R; Rivolti E; Mele G; Bari A; Mazzone C; Badiali S; Marcheselli L; Palumbo A; Morabito F
    Leuk Lymphoma; 2017 Mar; 58(3):552-559. PubMed ID: 27442600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
    Rodon P; Hulin C; Pegourie B; Tiab M; Anglaret B; Benboubker L; Jardel H; Decaux O; Kolb B; Roussel M; Garderet L; Leleu X; Fitoussi O; Chaleteix C; Casassus P; Lenain P; Royer B; Banos A; Benramdane R; Cony-Makhoul P; Dib M; Fontan J; Stoppa AM; Traullé C; Vilque JP; Pétillon MO; Mathiot C; Dejoie T; Avet-Loiseau H; Moreau P
    Haematologica; 2015 Feb; 100(2):e56-9. PubMed ID: 25398832
    [No Abstract]   [Full Text] [Related]  

  • 40. Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine.
    Yamasaki S; Kohno K; Kadowaki M; Takase K; Iwasaki H
    Ann Hematol; 2017 Jul; 96(7):1215-1217. PubMed ID: 28447162
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.